6 Nov 2018 07:00
6 November 2018
SalvaRx Group plc
("SalvaRx" or the "Company")
Director/PDMR Dealing
SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that the Company has issued and allotted 172,460 ordinary shares of 2.5 pence each in the capital of the Company at a price of 23.2p per share ("New Ordinary Shares"). The New Ordinary Shares rank pari passu with the existing Ordinary Shares and were issued following the exercise of options by Jim Mellon and Dr Greg Bailey, non-executive Directors of the Company. The gross proceeds of the exercise amounting to £40,010.72 were set off against amounts owing by the Company to Messrs Mellon and Bailey.
The options were exercised pursuant to the Rule 9 Waiver detailed in the Company's AIM admission document dated 3 March 2016. Following the issue of the New Ordinary Shares, the interests of Messrs Mellon and Bailey in the issued share capital of the Company are as follows:
Optionholder | Options exercised | Resultant interest in Ordinary Shares | % of enlarged share capital |
Jim Mellon | 86,230 | 13,406,521 | 36.53 |
Dr Greg Bailey | 86,230 | 13,406,521 | 36.53 |
The interest of Jim Mellon in the above table includes interests held through Galloway Limited and Port Erin Biopharma Investments Limited.
Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 9 November 2018.
Total Voting Rights
Following the issue of the New Ordinary Shares, the Company's issued ordinary share capital will comprise 36,699,642 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. This figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.
This announcement contains inside information.
Enquiries
SalvaRx Group plc | |
Ian B. Walters, MD (Chief Executive) | Tel: +1 203 441 5451 |
Northland Capital Partners Limited Nominated Adviser and Broker Matthew Johnson / Edward Hutton (Corporate Finance) Vadim Alexandre (Corporate Broking) | Tel: +44 (0) 20 3861 6625
|
The information below is set out in accordance with the requirements of the EU Market Abuse Regulation.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| James Mellon
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Director | |||
b)
| Initial notification /Amendment
| Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| SalvaRx Group plc | |||
b)
| LEI
| 213800G2OYVF7NTWRF98 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 2.5p each | |||
Identification code | IM00BZ4SS228 | ||||
| |||||
b)
| Nature of the transaction
| Exercise of options | |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
| 23.2p | 86,230 |
| ||
|
|
|
| ||
d)
| Aggregated information | ||||
- Aggregated volume | 86,230 | ||||
- Price | 23.2p | ||||
e)
| Date of the transaction
| 31 October 2018 | |||
f)
| Place of the transaction
| Outside a trading venue | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Gregory Bailey
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Director | |||
b)
| Initial notification /Amendment
| Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| SalvaRx Group plc | |||
b)
| LEI
| 213800G2OYVF7NTWRF98 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 2.5p each | |||
Identification code | IM00BZ4SS228 | ||||
| |||||
b)
| Nature of the transaction
| Exercise of options | |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
| 23.2p | 86,230 |
| ||
|
|
|
| ||
d)
| Aggregated information | ||||
- Aggregated volume | 86,230 | ||||
- Price | 23.2p | ||||
e)
| Date of the transaction
| 31 October 2018 | |||
f)
| Place of the transaction
| Outside a trading venue | |||